ILIAS Biologics Inc.
June 16, 2025
Company Presentation
Platform for Therapeutics
ILIAS Biologics Inc. is a clinical-stage biotech company specializing in exosome-based therapeutics. Our proprietary platform is designed to deliver a wide range of therapeutic modalities that target key intracellular signaling pathways, enabling innovative treatment approaches for complex diseases. We have completed a successful Phase 1 trial for ILB-202 and secured a Clinical Study Report.
We are advancing a differentiated pipeline that includes macrophage-targeted therapies for endometriosis and AMD, CNS-targeting exosomes for neurodegenerative disorders, and kidney- and liver-specific candidates for both acute and chronic conditions. Peer-reviewed publications and substantial public grant funding support our scientific foundation. We have also forged collaborations with major global pharmaceutical companies, accelerating development and commercialization. ILIAS is at the forefront of innovation in precision exosome therapeutics.
Company HQ City:
Daejeon
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2015
Lead Product in Development:
ILB-202
CEO
Chulhee Choi
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
1. Initiation of a Phase 1b/2a clinical trial for ILB-202 through strategic collaborations with global pharmaceutical partners
2. nonclinical development of our CNS- and kidney-targeted exosome programs
What is your next catalyst (value inflection) update?
September 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}